Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S. Canada Europe and Japan

ARQ252 potential to offer "Best in Class" topical JAK therapyPhase 2b study in adult patients with hand eczema anticipated to start in the first half of 2020WESTLAKE VILLAGE CA ACCESSWIRE January 13 2020 Arcutis Biotherapeutics Inc. A...